title: Cellular immunotherapy for soft tissue sarcomas.
abstract: Soft tissue sarcomas are rare neoplasms, with approximately 9000 new cases in the USA every year. Unfortunately, during the past two decades, there has been little progress in the treatment of metastatic soft tissue sarcomas beyond the standard approaches of surgery, chemotherapy and radiation. Immunotherapy is a modality complementary to conventional therapy. It is appealing because functional antitumor activity could affect both local-regional and systemic disease, and act over a prolonged period of time. In this report, we review immunotherapeutic investigative strategies that are being developed, including several tumor vaccine, antigen vaccine and dendritic cell vaccine strategies.
authors.affiliation: H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. sfinkels@rtsx.com
authors.forename: Steven Eric
authors.initials: SE
authors.lastname: Finkelstein
authors.forename: Mayer
authors.initials: M
authors.lastname: Fishman
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Conley
authors.forename: Dmitry
authors.initials: D
authors.lastname: Gabrilovich
authors.forename: Scott
authors.initials: S
authors.lastname: Antonia
authors.forename: Alberto
authors.initials: A
authors.lastname: Chiappori
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D017690:Cell Transplantation / Q000379:methods; D064987:Cell- and Tissue-Based Therapy; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009362:Neoplasm Metastasis; D012509:Sarcoma / Q000276:immunology / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines